Want to see HK:3347 full AI Analyst Report?
Hangzhou Tigermed Consulting Co., Ltd. Class H (3347) AI Stock Analysis
Top Page
Hangzhou Tigermed Consulting Co., Ltd. Class H
(HKEX:3347)
The score is held up by a conservatively financed balance sheet and continued positive free cash flow, but is weighed down by a sharp TTM profitability reset (net loss and margin compression) and clearly bearish technical momentum. Valuation is also constrained by negative earnings and a very low dividend yield.
Hangzhou Tigermed Consulting Co., Ltd. Class H (3347) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 42.54B
- Dividend Yield
- 0.38%
- Average Volume (3M)
- 1.56M
- Price to Earnings (P/E)
- -76.4
- Beta (1Y)
- 1.04
- Revenue Growth
- 21.72%
- EPS Growth
- -169.67%
- Country
- Hong Kong
- Employees
- 11,130
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Hangzhou Tigermed Consulting Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Hangzhou Tigermed Consulting Co., Ltd. provides clinical research services for research and development of domestic and foreign pharmaceutical and health related products. Its services include technical services for phase I to phase IV clinical trial...
Hangzhou Tigermed Consulting Co., Ltd. Class H Financial Statement Overview
Summary
Fundamentals are mixed: modest TTM revenue growth (~4.2%) and solid positive free cash flow (~1.12B) support resilience, and leverage is low (debt-to-equity ~0.11). Offsetting this, profitability weakened sharply with a swing to a TTM net loss (net margin ~-5.3%) and notable gross margin compression (~25.8% TTM vs ~33.9% in 2024).
Income Statement
52NeutralBalance Sheet
76PositiveCash Flow
68Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.59B | 6.83B | 6.60B | 7.38B | 7.09B | 5.21B |
| Gross Profit | 1.96B | 1.87B | 2.24B | 2.85B | 2.81B | 2.27B |
| EBITDA | 1.76B | 1.42B | 1.13B | 2.91B | 2.93B | 3.90B |
| Net Income | -270.08M | 887.89M | 405.14M | 2.02B | 2.01B | 2.87B |
Balance Sheet | ||||||
| Total Assets | 27.99B | 28.36B | 28.67B | 29.68B | 27.45B | 23.74B |
| Cash, Cash Equivalents and Short-Term Investments | 2.12B | 1.84B | 2.13B | 7.46B | 7.88B | 8.57B |
| Total Debt | 2.10B | 1.47B | 2.63B | 2.83B | 2.80B | 1.19B |
| Total Liabilities | 4.72B | 4.10B | 4.61B | 5.23B | 4.77B | 3.14B |
| Stockholders Equity | 19.64B | 20.96B | 20.67B | 21.03B | 19.58B | 18.12B |
Cash Flow | ||||||
| Free Cash Flow | 1.12B | 903.72M | 740.45M | 836.68M | 908.90M | 1.06B |
| Operating Cash Flow | 1.29B | 1.12B | 1.10B | 1.15B | 1.36B | 1.42B |
| Investing Cash Flow | -173.45M | 491.56M | -4.74B | -1.53B | -2.79B | -2.78B |
| Financing Cash Flow | -625.76M | -1.93B | -1.70B | -7.81M | 809.25M | -163.09M |
Hangzhou Tigermed Consulting Co., Ltd. Class H Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3347, the sentiment is Negative. The current price of 37.92 is below the 20-day moving average (MA) of 41.57, below the 50-day MA of 42.17, and below the 200-day MA of 41.15, indicating a bearish trend. The MACD of -1.55 indicates Positive momentum. The RSI at 37.92 is Neutral, neither overbought nor oversold. The STOCH value of 28.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3347.
Hangzhou Tigermed Consulting Co., Ltd. Class H Peers Comparison
Overall Rating
HK:226880Outperform
HK:235975Outperform
HK:612760Neutral- HK:334755Neutral
HK:666754Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2268 | 80Outperform | HKD 84.68B | 46.36 | 14.00% | ― | 41.52% | 17.10% |
| HK:2359 | 75Outperform | HKD 506.60B | 15.47 | 30.77% | 1.29% | 38.26% | 84.56% |
| HK:6127 | 60Neutral | HKD 36.16B | 29.06 | 13.10% | 0.60% | 16.68% | 442.43% |
| HK:3347 | 55Neutral | HKD 42.54B | -76.42 | -2.00% | 0.38% | 21.72% | -169.67% |
| HK:6667 | 54Neutral | HKD 1.59B | 50.49 | 4.04% | 2.40% | 169.02% | -24.61% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:3347 | Hangzhou Tigermed Consulting Co., Ltd. Class H | 37.92 | -8.52 | -18.35% | |
| HK:2359 | WuXi AppTec Co., Ltd. Class H | 185.40 | 83.35 | 81.67% | |
| HK:6127 | JOINN Laboratories (China) Co., Ltd. Class H | 22.88 | 2.30 | 11.20% | |
| HK:6667 | Mega Genomics Limited | 7.08 | 0.05 | 0.68% | |
| HK:9860 | ADICON Holdings Limited | 4.50 | -2.10 | -31.82% | |
| HK:2268 | WuXi XDC Cayman, Inc. | 66.65 | -6.05 | -8.32% |
Hangzhou Tigermed Consulting Co., Ltd. Class H Corporate Events
Hangzhou Tigermed Publishes Unaudited Q3 2026 Report Under Hong Kong Rules
Hangzhou Tigermed Consulting Co., Ltd., a Hong Kong-listed clinical research and pharmaceutical services provider, has released its third quarterly report for the 2026 financial year. The Group prepares its financial statements under China Accounting...
Tigermed Warns Investors as Subsidiary Frontage Faces Trading Halt on Potential Takeover News
Hangzhou Tigermed Consulting has disclosed that trading in the shares of its Hong Kong-listed subsidiary Frontage Holdings Corporation has been halted pending an announcement under the Code on Takeovers and Mergers that will contain inside informatio...
Tigermed Directors Fined Over Shareholding Disclosure Violations in China
Hangzhou Tigermed Consulting Co., Ltd., a leading Chinese clinical research and biopharmaceutical services group listed in Hong Kong, provides contract research and consulting support to pharmaceutical and biotech firms. Its business depends heavily...
Tigermed Sets Board Meeting to Approve Third-Quarter Results
Hangzhou Tigermed Consulting Co., Ltd. has scheduled a board meeting for October 29, 2026, to review and approve the group’s third quarterly report for the nine months ended September 30, 2026. The session may also consider additional resolutio...
Tigermed Adjusts 2026 Restricted Share Incentive Scheme After Shareholder Approval
Hangzhou Tigermed Consulting has secured shareholder approval for its 2026 Restricted A Share Incentive Scheme, including related management measures and authorisation for the board to administer the plan. The company also reported that internal insp...
Tigermed Shareholders Approve All Resolutions at 2026 Extraordinary Meetings
Hangzhou Tigermed Consulting Co., Ltd., a PRC-based contract research and clinical trial services provider listed via both A and H shares, held its 2026 third extraordinary general meeting and separate A share and H share class meetings in Hangzhou,...
Tigermed Directors Face Regulatory Warning and Fines Over Disclosure Lapses
Hangzhou Tigermed Consulting has disclosed that its directors and controlling shareholders, Mr. Ye Xiaoping and Ms. Cao Xiaochun, have received a formal warning letter from the Zhejiang arm of the China Securities Regulatory Commission for failing to...
Tigermed Calls 2026 EGM to Reshape Capital Structure and Launch New Share Incentive Plan
Hangzhou Tigermed Consulting has called a third extraordinary general meeting for September 23, 2026, in Hangzhou to seek shareholder approval for a wide-ranging package of capital and governance measures. The agenda includes changing the use of proc...
Tigermed Calls 2026 H Shareholders’ Meeting to Vote on Capital Reduction and New Buyback Mandate
Hangzhou Tigermed Consulting has called a third H share class meeting for September 23, 2026 in Hangzhou, to be held after its extraordinary general meeting and A share class meeting, with H shareholders of record on September 18 eligible to attend....
Tigermed Unveils 2026 Restricted A Share Incentive Scheme to Align Talent and Growth
Tigermed’s board has approved the proposed adoption of a 2026 Restricted A Share Incentive Scheme, accompanying assessment management measures, and authorization for the board to handle related implementation matters, all subject to shareholder...
Tigermed Cancels Remaining Treasury Shares to Cut Registered Capital
Hangzhou Tigermed Consulting Co., Ltd. has decided to cancel all remaining 5,883,780 A-share treasury shares previously repurchased under its 2024 buyback plan, shifting their intended use from future equity incentive or employee stock ownership sche...
Tigermed Board Approves New 2026 Plan for Remaining H Share Proceeds
Hangzhou Tigermed Consulting Co., Ltd., a Chinese clinical research services provider listed via H shares in Hong Kong, has raised net proceeds of approximately HK$11.8 billion from its H share offering. The company has repeatedly adjusted the deploy...
Tigermed Grows Revenue but Swings to Interim Loss on One-Off Items
Hangzhou Tigermed Consulting reported a 14.1% year-on-year rise in first-half 2026 revenue to RMB3.71 billion, with gross profit up 4.3% to RMB1.02 billion, reflecting continued business expansion in its contract research services. However, the compa...
Tigermed Sets August Board Meeting to Approve Interim Results and Weigh Dividend
Hangzhou Tigermed Consulting Co., Ltd. has scheduled a board meeting for August 28, 2026, to review and approve the unaudited interim results for the six months ended June 30, 2026, and to authorize their public release. The board will also consider...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026